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Juvenile nasopharyngeal angiofibroma (JNA) is a rare 
tumor in adolescent males. It originates in the nasopharynx. 
Aim: to present the experience of JNA management at 
an Otorhinolaryngology Service between 2001 and 2008. 
Materials and Methods: Demographical data, clinical 
presentation, investigations as well as the treatment of sixteen 
JNA patients were reviewed and collected from medical 
records from the ORL Service. Design: Cross-sectional, 
retrospective and descriptive study. Results: All JNA patients 
were male. The average age at diagnosis was 16.8 years (range 
9-23 years). More than 56% of the patients were classified 
as Fisch II. Preoperative embolization was carried out in ten 
(62.5%) patients. All 16 patients were submitted to primary 
surgical resection. Two patients (66.7%) who didn’t receive 
preoperative embolization required intraoperative blood 
transfusion. The overall recurrence rate was 43.75% and the 
cure rate was 93.75%. Conclusion: Preoperative embolization 
minimizes intraoperative blood loss. The recurrence rate was 
related to advanced tumoral stage at diagnostic and the 
lack of preoperative embolization. Surgery combined with 
preoperative embolization is the major treatment for JNA. All 
the patients should undergo preoperative imaging studies, 
especially CT, to assist in surgical planning and follow-up.
Keywords: angiofibroma, treatment, embolization, surgery, 
epistaxis
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INTRODUCTION
The juvenile nasopharyngeal angiofibroma is a rare 
benign vascular tumor representing about 0.5% of all head 
and neck neoplasms.1 Its incidence is 1:150,000, and it 
affects mostly male teenagers and young adults from ages 
14 to 25 years.2 A few cases have been reported in men 
over 25 years and in female teenagers.3-5
It is thought that the anatomical origin of this tumor 
is the postero/lateral wall of the nasal cavity, close to the 
superior border of the sphenopalatine foramen. This tu-
mor starts to grow on the submucosa of the floor of the 
nasopharynx, reaching the nasal septum and the posterior 
space of the nose, thereby causing a mass effect that may 
lead to airway obstruction. As the process is continuous, 
the anterior face of the sphenoidal sinus is destroyed and 
invaded. The tumor may grow towards the nasal fossa and 
extend to the posterior portion of the middle turbinate, 
which becomes a common part of the tumor mass. The 
angiofibroma may extend laterally towards the pterygoma-
xillary fossa and destroy the posterior wall of the maxillary 
sinus. Eventually, the tumor may invade the intratemporal 
fossa and the middle cranial fossa. This is a general view 
of the growth of this tumor. The actual modes of invasion 
into local structures may be unpredictable and far from a 
typical pattern.6,7
The macroscopic aspect of this tumor is a rounded, 
circumscribed, non-capsulated, mucosa-covered mass. The 
color depends on the vascular component; it may be pink-
and-wine-colored or pale-whitish. The maxillary artery 
supplies most of the blood to these tumors, with secondary 
contributions from the ipsilateral internal carotid artery or 
the contralateral external carotid system. The histological 
aspect of these tumors shows fibrous connective tissue 
and vessels. The periphery of the tumor is edematous and 
infiltrated, with necrosis and capillary vessels. The deeper 
vessels are larger and multiply anastomotic, similar to a 
cavernous hemangioma. The hemorrhagic feature of this 
tumor is due to a single endothelial cell layer with no 
smooth muscle and a rigid fibrous stroma.8-10
The site and extension of tumor invasion should 
be defined; not recognizing the anatomical site may result 
in a high rate of incomplete resections, which may alre-
ady be high because identifying the tumor capsule after 
prior embolization is difficult. Several staging systems 
have been proposed to make it possible to recognize the 
anatomical site of tumor invasion; Fisch’s classification11 is 
currently used most often. According to this classification, 
the angiofibroma is classified as Type I when the tumor 
is restricted to the nasal cavity and the nasopharynx wi-
thout bone destruction; Type II when the tumor invades 
the pterygomaxillary fossa and maxillary, sphenoidal and 
ethmoid sinuses with bone destruction; Type III when the 
tumor invades the intratemporal fossa, the orbit and the 
parasellar region, but remaining lateral to the cavernous 
sinus; and Type IV when the tumor invades the cavernous 
sinus, the optic chiasma, and the pituitary fossa.11
The classical clinical presentation of the angiofibro-
ma is unilateral nasal block and/or epistaxis, rhinorrhea, 
and occasionally pain. Because of its invasive nature, the 
tumor may cause facial deformity, and proptosis, changes 
in visual acuity and cranial nerve palsy if it reaches the 
orbit and intracranial region.12,13 
The diagnosis of angiofibroma is essentially based 
on a careful clinical history and a detailed physical exa-
mination to describe the signs and symptoms, the mor-
phology and epidemiology, and the radiological findings. 
Imaging techniques have led to major advances in the diag-
nosis and treatment of angiofibromas. Nasal endoscopy, 
computed tomography, and magnetic resonance imaging 
help establish the site and extension of this tumor and the 
relations with blood vessels and nerves, all of which make 
it possible to precisely stage the tumor. Biopsies are not 
recommended because of the vascular and hemorrhagic 
nature of this tumor. Arteriography is done to assess the 
vascular supply in larger tumors and to make it possible 
to embolize these vascular lesions to reduce intraoperative 
bleeding.14-16
Several tumoral or non-tumoral diseases may cau-
se nasal block and epistaxis, which may be taken for an 
angiofibroma. The following conditions should be taken 
into account in the differential diagnosis: inflammatory 
polyps, angiomatous polyps, nasopharyngeal cysts, naso-
pharyngeal malignancies, nasopharyngeal fibrosarcomas 
and fibromas, upper maxillary malignancies, nasal fossa 
stesioneuroblastoma, adenoid hypertrophy, cervical verte-
bra cordomas, and retropharyngeal ganglia tuberculosis.16
Several surgical approaches have been described 
for the treatment of angiofibromas; these include the 
transpalatine approach, lateral rhinotomy, and medio-facial 
degloving. In any of these techniques, the recommended 
treatment of choice is preoperative tumor embolization 
to decrease intraoperative bleeding when removing the 
angiofibroma.15-22
This study reports the experience of an Otorhino-
laryngology and Head & Neck Surgery Department in a 
school hospital from 2001 to 2008 with the diagnosis and 
treatment results of patients with juvenile nasopharyngeal 
angiofibroma.
SERIES AND METHOD
The institutional review board of our institution ap-
proved this study (protocol no. 3644/2009), in accordance 
with the regulating guidelines for research on humans in 
Resolution 196/96, of the Ministry of Health.
A cross-sectional retrospective study was carried 
out using data from a review of the records of 16 patients 
diagnosed with angiofibromas, from 2001 to 2008. The free 
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informed consent form was not needed in this context.
The following data were gathered: gender, age at 
the time of diagnosis, signs and symptoms, diagnostic 
examination, surgical approach, need for transfusion, 
preoperative embolization, complications, follow-up exa-
ms, recurrences, and reoperation. The Fisch (Fisch, 1983) 
criteria were applied to classify the tumors.
Percentages (%) were calculated and their standard 
deviations (SD), which were expressed as percentages 
(SD%).
RESULTS
From 2001 to 2008, 16 male patients (100%) un-
derwent treatment for angiofibromas. The ages ranged 
from 9 to 23 years, with a mean 16.8 years (SDM= 0.885). 
One patient (6.25%, SD%=24.20) was a child (7 to 10 years), 
6 patients (37.5%, SD%=19.76) were teenagers (11 to 16 
years), and 9 patients (56.25%, SD%=16.53) were young 
adults (17 to 25 years) at the time of diagnosis.
The most frequent signs and/or symptoms were 
epistaxis (93.75%, SD%=6.25) and nasal block (75%, 
SD%=12.5), followed by hyposmia (12.5%, SD%=23.38), 
bulging of the face (6.25%, DP%=24.20), and decreased 
visual acuity (6.25%, SD%=24.20). No patient reported 
rhinorrhea.
All patients underwent nasal endoscopy and com-
puted tomography. No biopsies were carried out in these 
patients.
Table1. Patient data in relation to age at diagnosis, the need for embolization, surgical approach, and postoperative complications.
Patient Fisch11 staging
Age at diag-
nosis
Preoperative 
embolization
Time between 
embolization 
and surgery
Surgical approach
Intraoperative 
transfusion
Postoperative 
complications
1 II 19y6m Yes 48 hs Nasal endoscopy --- ---
2 III 14y10m Yes 48 hs
Medio-facial degloving 
+ Denker
--- ---
3 III 15y7m Yes 48 hs
Medio-facial degloving 
+ Denker
3U  
4 II 17y10m Yes 48 hs
Medio-facial degloving 
+ Denker
--- ---
5 II 12y2m Yes 48 hs
Medio-facial degloving 
+ Denker
--- ---
6 II 23y3m Yes 48 hs
Medio-facial degloving 
+ Denker
--- ---
7 II 20y Yes 48 hs
Medio-facial degloving 
+ Denker
--- ---
8 I 20y5m Yes 48 hs
Medio-facial degloving 
+ Denker
--- ---
9 II 17y6m Yes 48 hs
Medio-facial degloving 
+ Denker + nasal 
endoscopy
--- ---
10 II 15y7m Yes 48 hs
Medio-facial degloving 
+ Denker
--- ---
11 III 17y4m No --- LeFort I osteotomy 3U ---
12 II 15y11m No ---
Medio-facial degloving 
+ Denker
6U ---
13 I 9y1m No ---
Medio-facial degloving 
+ Denker +  nasal 
endoscopy
--- ---
14 II 16y5m No --- Transpalatine --- ---
15 I 21y4m No --- Transpalatine --- Oroantral leak
16 I 19y11m No --- Nasal endoscopy ---
Lower turbinate 
and nasal sep-
tum synechia
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Based on the tomographic findings and the Fisch 
classification,11 4 patients (25.0%, SD%=21.65) were stage 
I, 9 patients (56.25%, SD%=16.53) were stage II, 3 patients 
(18.75%, SD%=15.61) were stage III, and there were no 
stage IV patients (0%).
Ten patients (62.5%, SD%=15.30) underwent arte-
riography with superselective embolization of branches 
of the maxillary artery 48 hours prior to surgery, with no 
complications.
All patients underwent surgery, as follows: me-
dial facial degloving + Denker in 9 patients (56.25%, 
SD%=16.53), medial facial degloving + Denker + nasal 
endoscopy in 2 patients (12.5%, SD%=23.38), transpalatine 
in 2 patients (12.5%, SD%=23.38), nasal endoscopy in 2 
patients (12.5%, SD%=23.38), and the LeFort I osteotomy 
in 1 (6.25%, SD%=24.20).
Three patients (18.75%, SD%=22.53) required intra-
operative blood transfusions, of which 2 patients (66.67%, 
Table 2. Patient data in relation to procedures after recurrences and follow-up.
Patient
Fisch11 sta-
ging
Recurrence/
time after 1st 
surgery
Diagnostic 
exam
Reoperation
Intraoperative 
transfusion
Postopera-
tive compli-
cation
Follow-up/
Exams
New
recurrence 
until 2008
1 II No --- --- --- ---
Quarterly/
TC+ control
No
2 III Yes/5 months
Nasofibros-
copy
RM*
Degloving 
MF+
+ Nasal 
endoscopic 
review
--- ---
Quarterly/
TC+ control
No
3 III Yes/2 months TC+
Nasal endos-
copic review
Quarterly/
TC+ control
No
4 II No --- --- --- ---
Quarterly/
TC+ control
No
5 II No --- --- --- ---
Quarterly/
TC+ control
No
6 II No --- --- --- ---
Quarterly/
TC+ control
No
7 II No --- --- --- ---
Quarterly/
TC+ control
No
8 I No --- --- --- ---
Quarterly/
TC+ control
No
9 II No --- --- --- ---
Quarterly/
TC+ control
No
10 II Yes/1 month
Nasofibros-
copy
Nasal endos-
copic review
--- ---
Quarterly/
TC+ control
No
11 III
Yes/10 
months
TC+
Degloving 
MF++ Nasal 
endoscopic 
review
--- ---
Quarterly/
TC+ control
No
12 II Yes/5 months TC+
Degloving 
MF+
4U
Fissura 
palatina
Quarterly/
TC+ control
No
13 I Yes/3 years
Nasofibros-
copy
Nasal endos-
copic revision
--- ---
Quarterly/
TC+ control
No
14 II Yes/2 years TC+
LeFort I osteo-
tomy
1U  
Quarterly /
TC+ control 
until 2006
No
until 2006
15 I No --- --- --- ---
Quarterly/
TC+ control
No
16 I No --- --- --- ---
Quarterly/
TC+ control No
*RM-Magnetic Resonance, +TC-Computed Tomography, +Medio-facial degloving
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SD%=33.33) had not done preoperative embolization.
Nasal packing was done in all patients at the end 
of surgery and removed 48 to 72 hours later.
Only 2 patients (12.5%, SD%=23.38) had postope-
rative complications, such as an oroantral leak following 
a transpalatine approach, and lower turbinate and septal 
synechiae after nasal endoscopy; both complications were 
corrected with no additional morbidity.
Tumors recurred in 1 of 4 stage I patients (25%, 
SD%=43.30), 3 of 9 stage II patients (33%, SD%=27.14), 
and 3 of 3 stage III patients (100%). Preoperative embo-
lization had been carried out in 3 (43%, DP%=28.58) of 
these 7 patients, and not on the remaining 4 patients (57%, 
SD%=24.75). The recurrence rate was 43.75% (SD%=18.75). 
The time to relapse after surgery ranged from 1 month 
to 3 years; all 7 patients were reoperated. Of these, only 
1 (14.3%, SD%=35.0) presented a palatine fissure as a 
complication of reoperation, which was also corrected.
Follow-up of 15 patients is being done quarterly, 
except for one patient who abandoned follow-up since 
2006; these patients undergo computed tomography for 
monitoring purposes, and no recurrences have been found 
to date. The follow-up time has ranged from 1 to 6 years; 
the mean is 2.3 years (SDM= 1.77). Based on this, the cure 
rate is 93.75% (SD%=6.25).
Tables 1 and 2 show the data gathered from 16 
patient files.
DISCUSSION
The juvenile nasopharyngeal angiofibroma is, 
as the name suggests, a disease of young men.6 In the 
present study, all patients were male, and the mean age 
at the time of diagnosis was 16.8 years, which is similar 
to other published studies.13-15,20,23 Genetic studies have 
demonstrated a close relation between these angiomas 
and androgen receptor expression, suggesting that this 
tumor is androgen-dependent. This could explain why 
the prevalence is higher in males.24-25
In most cases, the clinical presentation of the an-
giofibroma comprises the triad nose block, epistaxis, and 
a nasopharyngeal mass, which was similar to our findings 
in the study and in previously published papers.13,14,26,27
The diagnosis of angiofibroma is given based on 
the clinical history, the physical examination, and nasal 
endoscopy; imaging studies, such as computed tomogra-
phy, may add further information, as was done in the 
patients comprising this study. The correlation between 
preoperative staging based on computed tomography and 
the Fisch criteria11 was possible in the 16 cases of this 
study. Computed tomography makes it possible to stage 
tumors correctly, and may demonstrate the presence and 
extension of recurrences during follow-up.16,28
All patients underwent surgery, which is the most 
effective therapy for angiofibromas. There is no consensus 
on which surgical procedure is best; the most frequently 
used approach today is the transmaxillary route, which 
allows better exposure of the tumor, lower morbidity, and 
no facial scars.29
The cure rate, according to the follow-up time of 
these patients, was 93.75%, which was similar to other 
published results.15,26
Some studies have reported that better control of 
surgical bleeding has been associated with improved sup-
port for surgery, such as embolization done 24 to 48 hours 
preoperatively, updated surgical techniques, and profes-
sional experience. Embolization may significantly decrease 
intraoperative bleeding by reducing tumor size, thereby 
facilitating its removal. As a result, there are low recurrence 
rates following preoperative embolization. Embolization of 
the maxillary artery is a relatively safe invasive procedure; 
a complication of this procedure is embolism into the 
intracranial circulation, but this event is rare.15-22,30 In the 
present study, 62.5% of patients underwent embolization 
without complications; only 2 patients (12.5%) were not 
embolized, and required intraoperative blood transfusions. 
These results are similar to other published results.15-22,30
Although the recurrence rate is lower in patients that 
were embolized,20,21,30 a few studies have shown opposite 
results, suggesting that embolization could make it more 
difficult to identify the full extension of surgical margins, 
as the tumor becomes smaller; this would increase the 
recurrence rate.31,32 Our findings were different, since 57% 
of the 7 patients in which the tumor recurred had not un-
dergone embolization; this is similar to published results, 
which range from 0% to 57%.33 These findings show that 
decreased bleeding during surgery considerably facilita-
tes tumor removal, decreases the need for intraoperative 
transfusions, and reduces the recurrence rate in patients 
undergoing preoperative embolization, as was the case 
in our sample.18,20,21
CONCLUSION
The recurrence rate was associated with the absence 
of preoperative embolization and advanced tumor stage 
at the time of diagnosis.
Preoperative selective arterial embolization was 
the best treatment for angiofibromas among the cases we 
reviewed; the cure rate was about 94%.
All patients diagnosed with angiofibroma should 
be investigated with imaging methods, such as computed 
tomography, and preoperative embolization, to improve 
surgical planning and reduce intraoperative bleeding.
Follow-up using computed tomography makes it 
possible to establish the presence and extension of tumor 
recurrences, or the absence of tumors.
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